{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:00:24Z","timestamp":1790002824465,"version":"4.0.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"he Natural Science Foundation of Gansu Province, China","award":["24ZDFA006"],"award-info":[{"award-number":["24ZDFA006"]}]},{"name":"Major Projects of the Joint Scientific Research Fund of Gansu Province","award":["23JRRA1501"],"award-info":[{"award-number":["23JRRA1501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10096-026-05579-1","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:26:15Z","timestamp":1782840375000},"page":"2637-2648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tetracycline for Helicobacter pylori eradication: a narrative review from quadruple to dual therapy"],"prefix":"10.1007","volume":"45","author":[{"given":"Xiaojuan","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dekui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"5579_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","volume":"8","author":"Y Li","year":"2023","unstructured":"Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK (2023) Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 8:553\u2013564","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5579_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","volume":"166","author":"YC Chen","year":"2024","unstructured":"Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT et al (2024) Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology 166:605\u2013619","journal-title":"Gastroenterology"},{"key":"5579_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","volume":"9","author":"P Malfertheiner","year":"2023","unstructured":"Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C et al (2023) Helicobacter pylori infection. Nat Rev Dis Primers 9:19","journal-title":"Nat Rev Dis Primers"},{"key":"5579_CR4","doi-asserted-by":"publisher","first-page":"835313","DOI":"10.3389\/fmicb.2022.835313","volume":"13","author":"AN Nath","year":"2022","unstructured":"Nath AN, Retnakumar RJ, Francis A, Chhetri P, Thapa N, Chattopadhyay S (2022) Peptic Ulcer and Gastric Cancer: Is It All in the Complex Host-Microbiome Interplay That Is Encoded in the Genomes of Us and Them? Front Microbiol 13:835313","journal-title":"Front Microbiol"},{"key":"5579_CR5","doi-asserted-by":"publisher","first-page":"S418","DOI":"10.1093\/infdis\/jiaf402","volume":"232","author":"C Liang","year":"2025","unstructured":"Liang C, Zhou Y, Li Y, Xu M, Li C (2025) Follow-up and Analysis of Helicobacter pylori Antibiotic Resistance in the South Area of Sichuan Province. J Infect Dis 232:S418\u2013s24","journal-title":"J Infect Dis"},{"key":"5579_CR6","doi-asserted-by":"publisher","first-page":"45439","DOI":"10.1038\/s41598-025-29451-y","volume":"15","author":"W Tao","year":"2025","unstructured":"Tao W, Ma W, Zhao G, Zhang Z, Xu C, Wang P et al (2025) Characterization of antibiotic resistance and biofilm formation in clinical Helicobacter pylori isolates from Ningxia, China. Sci Rep 15:45439","journal-title":"Sci Rep"},{"key":"5579_CR7","doi-asserted-by":"publisher","first-page":"1392787","DOI":"10.3389\/fphar.2024.1392787","volume":"15","author":"D Zhou","year":"2024","unstructured":"Zhou D, Wang W, Gu L, Han M, Hao W, Huang J et al (2024) Helicobacter pylori antibiotic resistance profile in Chinese children with upper gastrointestinal symptoms and a literature review for developing personalized eradicating strategies. Front Pharmacol 15:1392787","journal-title":"Front Pharmacol"},{"key":"5579_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s12325-016-0345-2","volume":"33","author":"K Otake","year":"2016","unstructured":"Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H et al (2016) Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). Adv Ther 33:1140\u20131157","journal-title":"Adv Ther"},{"key":"5579_CR9","doi-asserted-by":"publisher","first-page":"e13102","DOI":"10.1111\/hel.13102","volume":"29","author":"Z Han","year":"2024","unstructured":"Han Z, Zhang Q, Mirza IA, Ding Y, Nan X, Zhao Q et al (2024) Efficacy of Tetracycline Three Times Daily was Comparable to That of Four Times Daily for Helicobacter pylori Rescue Treatment: A Multicenter, Noninferiority, Randomized Controlled Trial. Helicobacter 29:e13102","journal-title":"Helicobacter"},{"key":"5579_CR10","doi-asserted-by":"publisher","first-page":"e13121","DOI":"10.1111\/hel.13121","volume":"29","author":"YM Ding","year":"2024","unstructured":"Ding YM, Zhang QM, Li RL, Han ZX, Zhao Q, Xu LD et al (2024) Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial. Helicobacter 29:e13121","journal-title":"Helicobacter"},{"key":"5579_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M et al (2020) Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut 69:1019\u20131026","journal-title":"Gut"},{"key":"5579_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jgh3.12852","volume":"7","author":"S Sue","year":"2023","unstructured":"Sue S, Kondo M, Sato T, Oka H, Sanga K, Ogashiwa T et al (2023) Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: A single-arm, interventional study. JGH Open 7:55\u201360","journal-title":"JGH Open"},{"key":"5579_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1749-6632.2011.06254.x","volume":"1241","author":"BM Duggar","year":"2011","unstructured":"Duggar BM (2011) Aureomycin: a product of the continuing search for new antibiotics. Ann N Y Acad Sci 1241:163\u2013169","journal-title":"Ann N Y Acad Sci"},{"key":"5579_CR14","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.3748\/wjg.v30.i17.2354","volume":"30","author":"K Zhou","year":"2024","unstructured":"Zhou K, Li CL, Zhang H, Suo BJ, Zhang YX, Ren XL et al (2024) Minocycline in the eradication of Helicobacter pylori infection: A systematic review and meta-analysis. World J Gastroenterol 30:2354\u20132368","journal-title":"World J Gastroenterol"},{"key":"5579_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00535-023-01991-y","volume":"58","author":"Y Huang","year":"2023","unstructured":"Huang Y, Chen J, Ding Z, Chen X, Liang X, Zeng X et al (2023) Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial. J Gastroenterol 58:633\u2013641","journal-title":"J Gastroenterol"},{"key":"5579_CR16","doi-asserted-by":"crossref","unstructured":"Wazir HU, Khuram AM, Reza IMK, Ajmal H, Parveen H, Ahmed Z et al (2026) Efficacy and safety of minocycline-containing bismuth quadruple therapies versus standard first-line bismuth quadruple therapies for Helicobacter pylori eradication: a systematic review and meta-analysis. Infect Dis Rep 18:16","DOI":"10.3390\/idr18010016"},{"key":"5579_CR17","doi-asserted-by":"publisher","first-page":"e12839","DOI":"10.1111\/hel.12839","volume":"26","author":"J Zhao","year":"2021","unstructured":"Zhao J, Zou Y, Li K, Huang X, Niu C, Wang Z et al (2021) Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis. Helicobacter 26:e12839","journal-title":"Helicobacter"},{"key":"5579_CR18","doi-asserted-by":"crossref","unstructured":"Kounatidis D, Dalamaga M, Grivakou E, Karampela I, Koufopoulos P, Dalopoulos V et al (2024) Third-generation tetracyclines: Curr Knowl Therapeutic Potential Biomolecules 14:783","DOI":"10.3390\/biom14070783"},{"key":"5579_CR19","doi-asserted-by":"crossref","unstructured":"Alegun O, Pandeya A, Cui J, Ojo I, Wei Y (2021) Donnan potential across the outer membrane of gram-negative bacteria and its effect on the permeability of antibiotics. Antibiot (Basel) 10:701","DOI":"10.3390\/antibiotics10060701"},{"key":"5579_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","volume":"65","author":"I Chopra","year":"2001","unstructured":"Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232\u2013260 second page, table of contents","journal-title":"Microbiol Mol Biol Rev"},{"key":"5579_CR21","doi-asserted-by":"crossref","unstructured":"Semenova Y, Makalkina L, Glushkova N, Gaipov A (2025) Tetracyclines in the modern era: global consumption, antimicrobial resistance, environmental occurrence, and degradation techniques. Antibiot (Basel) 14:1183","DOI":"10.3390\/antibiotics14121183"},{"key":"5579_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jac\/dkl224","volume":"58","author":"KN Agwuh","year":"2006","unstructured":"Agwuh KN, MacGowan A (2006) Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58:256\u2013265","journal-title":"J Antimicrob Chemother"},{"key":"5579_CR23","doi-asserted-by":"publisher","first-page":"107325","DOI":"10.1016\/j.ijantimicag.2024.107325","volume":"64","author":"S Zeng","year":"2024","unstructured":"Zeng S, Kong Q, Wu X, Duan M, Nan X, Yang X et al (2024) Antibiotic resistance of Helicobacter pylori in Mainland China: A focus on geographic differences through systematic review and meta-analysis. Int J Antimicrob Agents 64:107325","journal-title":"Int J Antimicrob Agents"},{"key":"5579_CR24","doi-asserted-by":"publisher","first-page":"e71238","DOI":"10.1002\/hsr2.71238","volume":"8","author":"S Menbari","year":"2025","unstructured":"Menbari S, Shahsavar SK, Keikha M, Karbalaei M (2025) Global Profile of Drug Resistance Related to Helicobacter pylori Infection in Children: A Systematic Review and Meta-Analysis. Health Sci Rep 8:e71238","journal-title":"Health Sci Rep"},{"key":"5579_CR25","doi-asserted-by":"publisher","first-page":"1510376","DOI":"10.3389\/fmed.2024.1510376","volume":"11","author":"X Su","year":"2024","unstructured":"Su X, Deng Y, Chen X, Li Y, Hao Q, Tang Y et al (2024) Effect of an individualized bismuth quadruple regimen guided by 10-day or 14-day antibiotic susceptibility testing for first-line eradication treatment of Helicobacter pylori in Ningxia, China. Front Med (Lausanne) 11:1510376","journal-title":"Front Med (Lausanne)"},{"key":"5579_CR26","doi-asserted-by":"publisher","first-page":"e12960","DOI":"10.1111\/hel.12960","volume":"28","author":"S Hu","year":"2023","unstructured":"Hu S, Zhou Y, Deng Y, Bo Y, Chen X, Yang W et al (2023) Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia. Helicobacter 28:e12960","journal-title":"Helicobacter"},{"key":"5579_CR27","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1128\/AAC.46.9.2996-3000.2002","volume":"46","author":"MM Gerrits","year":"2002","unstructured":"Gerrits MM, de Zoete MR, Arents NL, Kuipers EJ, Kusters JG (2002) 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 46:2996\u20133000","journal-title":"Antimicrob Agents Chemother"},{"key":"5579_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1099\/00222615-44-6-425","volume":"44","author":"JE Sj\u00f6str\u00f6m","year":"1996","unstructured":"Sj\u00f6str\u00f6m JE, Larsson H (1996) Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. J Med Microbiol 44:425\u2013433","journal-title":"J Med Microbiol"},{"key":"5579_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5223\/pghn.2015.18.4.246","volume":"18","author":"JH Seo","year":"2015","unstructured":"Seo JH, Park HK, Park JS, Yeom JS, Lim JY, Park CH et al (2015) Association between Gastric pH and Helicobacter pylori Infection in Children. Pediatr Gastroenterol Hepatol Nutr 18:246\u2013252","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"5579_CR30","doi-asserted-by":"publisher","first-page":"1523399","DOI":"10.3389\/fphar.2025.1523399","volume":"16","author":"A Ibrahim","year":"2025","unstructured":"Ibrahim A, Yusuff K, Awaisu A, Elewa H (2025) Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review. Front Pharmacol 16:1523399","journal-title":"Front Pharmacol"},{"key":"5579_CR31","first-page":"e65141","volume":"16","author":"DE Agago","year":"2024","unstructured":"Agago DE, Hanif N, Ajay Kumar AS, Arsalan M, Kaur Dhanjal M, Hanif L et al (2024) Comparison of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus 16:e65141","journal-title":"Cureus"},{"key":"5579_CR32","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","volume":"117","author":"L Laine","year":"2022","unstructured":"Laine L, Sharma P, Mulford DJ, Hunt B, Leifke E, Smith N et al (2022) Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects. Am J Gastroenterol 117:1158\u20131161","journal-title":"Am J Gastroenterol"},{"key":"5579_CR33","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s12916-024-03816-y","volume":"22","author":"A Salahi-Niri","year":"2024","unstructured":"Salahi-Niri A, Nabavi-Rad A, Monaghan TM, Rokkas T, Doulberis M, Sadeghi A et al (2024) Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis. BMC Med 22:598","journal-title":"BMC Med"},{"key":"5579_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11096-022-01397-5","volume":"44","author":"C Wei","year":"2022","unstructured":"Wei C, Liu Y, Jiang A, Wu B (2022) A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data. Int J Clin Pharm 44:709\u2013716","journal-title":"Int J Clin Pharm"},{"key":"5579_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jama.2018.19283","volume":"321","author":"ES Shenoy","year":"2019","unstructured":"Shenoy ES, Macy E, Rowe T, Blumenthal KG (2019) Evaluation and Management of Penicillin Allergy: A Review. JAMA 321:188\u2013199","journal-title":"JAMA"},{"key":"5579_CR36","doi-asserted-by":"crossref","unstructured":"Duman E, M\u00fcller-Deubert S, Pattappa G, Stratos I, Sieber SA, Clausen-Schaumann H et al (2025) Fluoroquinolone-mediated tendinopathy tendon rupture. Pharmaceuticals (Basel) 18:184","DOI":"10.3390\/ph18020184"},{"key":"5579_CR37","doi-asserted-by":"crossref","unstructured":"Iqbal F, Derouen A, Ren R, Kaye AM, Ahmadzadeh S, Shekoohi S et al (2025) Macrolide antibiotic mediated cardiac arrhythmias: emerging concepts and clinical implications. Biomedicines 13:1478","DOI":"10.3390\/biomedicines13061478"},{"key":"5579_CR38","doi-asserted-by":"publisher","first-page":"102826","DOI":"10.1016\/j.jiac.2025.102826","volume":"31","author":"J Hirai","year":"2025","unstructured":"Hirai J, Arakawa Y, Kato H, Takano T, Yamagishi Y, Kunishima H et al (2025) Comparative efficacy and safety of oral versus intravaginal metronidazole for the treatment of bacterial vaginosis: A systematic review and meta-analysis. J Infect Chemother 31:102826","journal-title":"J Infect Chemother"},{"key":"5579_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5694\/j.1326-5377.1990.tb136833.x","volume":"153","author":"LL George","year":"1990","unstructured":"George LL, Borody TJ, Andrews P, Devine M, Moore-Jones D, Walton M et al (1990) Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 153:145\u2013149","journal-title":"Med J Aust"},{"key":"5579_CR40","doi-asserted-by":"publisher","first-page":"e12570","DOI":"10.1111\/hel.12570","volume":"24","author":"OP Nyssen","year":"2019","unstructured":"Nyssen OP, McNicholl AG, Gisbert JP (2019) Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter 24:e12570","journal-title":"Helicobacter"},{"key":"5579_CR41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","volume":"377","author":"P Malfertheiner","year":"2011","unstructured":"Malfertheiner P, Bazzoli F, Delchier JC, Celi\u00f1ski K, Gigu\u00e8re M, Rivi\u00e8re M et al (2011) Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 377:905\u2013913","journal-title":"Lancet"},{"key":"5579_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000487391","volume":"36","author":"A Tursi","year":"2018","unstructured":"Tursi A, Franceschi M, Allegretta L, Savarino E, De Bastiani R, Elisei W et al (2018) Effectiveness and Safety of Pylera\u00ae in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. Dig Dis 36:264\u2013268","journal-title":"Dig Dis"},{"key":"5579_CR43","doi-asserted-by":"publisher","first-page":"102689","DOI":"10.1016\/j.clinre.2025.102689","volume":"49","author":"MP Dore","year":"2025","unstructured":"Dore MP, Merola E, Pes GM (2025) Advances and future perspectives in the pharmacological treatment of Helicobacter pylori infection: Taking advantage from artificial intelligence. Clin Res Hepatol Gastroenterol 49:102689","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"5579_CR44","doi-asserted-by":"publisher","first-page":"175628482211381","DOI":"10.1177\/17562848221138168","volume":"15","author":"CA Shih","year":"2022","unstructured":"Shih CA, Shie CB, Hsu PI (2022) Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances. Th Adv Gastroenterol 15:17562848221138168","journal-title":"Th Adv Gastroenterol"},{"key":"5579_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1756283X11432492","volume":"5","author":"F M\u00e9graud","year":"2012","unstructured":"M\u00e9graud F (2012) The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Th Adv Gastroenterol 5:103\u2013109","journal-title":"Th Adv Gastroenterol"},{"key":"5579_CR46","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/apt.70535","volume":"63","author":"JP Gisbert","year":"2026","unstructured":"Gisbert JP, Parra P, Nyssen OP (2026) Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice. Aliment Pharmacol Ther 63:616\u2013636","journal-title":"Aliment Pharmacol Ther"},{"key":"5579_CR47","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1097\/MJT.0000000000000389","volume":"24","author":"H Alkim","year":"2017","unstructured":"Alkim H, Koksal AR, Boga S, Sen I, Alkim C (2017) Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther 24:e751\u2013e7","journal-title":"Am J Ther"},{"key":"5579_CR48","doi-asserted-by":"crossref","unstructured":"Woo J, Bang CS, Lee JJ, Ahn JY, Kim JM, Jung HY et al (2024) In vitro susceptibility and synergistic effect of bismuth against Helicobacter pylori. Antibiot (Basel) 13:1004","DOI":"10.3390\/antibiotics13111004"},{"key":"5579_CR49","unstructured":"Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C et al (2022) Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut"},{"key":"5579_CR50","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","volume":"119","author":"WD Chey","year":"2024","unstructured":"Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S et al (2024) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 119:1730\u20131753","journal-title":"Am J Gastroenterol"},{"key":"5579_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/gutjnl-2024-332804","volume":"74","author":"L Olmedo","year":"2024","unstructured":"Olmedo L, Calvet X, Gen\u00e9 E, Bordin DS, Voynovan I, Castro-Fernandez M et al (2024) Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). Gut 74:15\u201325","journal-title":"Gut"},{"key":"5579_CR52","doi-asserted-by":"publisher","first-page":"1667516","DOI":"10.3389\/fmicb.2025.1667516","volume":"16","author":"K Ju","year":"2025","unstructured":"Ju K, Kong Q, Zhang S, Zhu L, Li Y (2025) Amoxicillin or tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Front Microbiol 16:1667516","journal-title":"Front Microbiol"},{"key":"5579_CR53","doi-asserted-by":"publisher","first-page":"2464938","DOI":"10.1080\/07853890.2025.2464938","volume":"57","author":"J Xie","year":"2025","unstructured":"Xie J, Peng J, Wu S, Yang K, Liu D, Shen L et al (2025) Efficacy and safety of tetracycline vs. amoxicillin in furazolidone-based rescue therapy for Helicobacter pylori: a real-world analysis. Ann Med 57:2464938","journal-title":"Ann Med"},{"key":"5579_CR54","doi-asserted-by":"crossref","unstructured":"Cho JH, Jin SY (2025) Efficacy and safety of modified bismuth quadruple therapy for first-line Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials. Microorganisms 13:519","DOI":"10.3390\/microorganisms13030519"},{"key":"5579_CR55","first-page":"220","volume":"64","author":"BJ Suo","year":"2025","unstructured":"Suo BJ, Zhang YX, Li CL, Zhou LY, Song ZQ (2025) [Clinical characteristic analysis of refractory Helicobacter pylori infection of 637 patients]. Zhonghua nei ke za zhi 64:220\u2013224","journal-title":"Zhonghua nei ke za zhi"},{"key":"5579_CR56","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/jac\/dkp034","volume":"63","author":"CH Kuo","year":"2009","unstructured":"Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ et al (2009) Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 63:1017\u20131024","journal-title":"J Antimicrob Chemother"},{"key":"5579_CR57","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1046\/j.1365-2036.2001.01064.x","volume":"15","author":"M Guslandi","year":"2001","unstructured":"Guslandi M (2001) Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther 15:1543\u20131547","journal-title":"Aliment Pharmacol Ther"},{"key":"5579_CR58","doi-asserted-by":"crossref","unstructured":"Resina E, Gisbert JP (2021) Rescue therapy with furazolidone in patients with at least five eradication treatment failures and multi-resistant H. pylori infection. Antibiot (Basel) 10:1028","DOI":"10.3390\/antibiotics10091028"},{"key":"5579_CR59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cgh.2025.06.029","volume":"24","author":"SA Merchant","year":"2026","unstructured":"Merchant SA, Badalov JM, Shah SC, Corley DA, Li D (2026) Comparative Effectiveness of Empiric Treatment for Helicobacter pylori in a Large, Diverse Population in the United States. Clin Gastroenterol Hepatol 24:92\u2013102e8","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5579_CR60","doi-asserted-by":"publisher","first-page":"e70077","DOI":"10.1111\/hel.70077","volume":"30","author":"BSF Sanches","year":"2025","unstructured":"Sanches BSF, Nyssen OP, Chaves SR, Veloso JS, Silva LS, Marinho JR et al (2025) Empirical Rescue Eradication Therapy for Helicobacter pylori Infection in Second and Subsequent Treatment Lines: Experience From 500 Cases of the Brazilian Registry on H. pylori Management (Hp-BrazilReg). Helicobacter 30:e70077","journal-title":"Helicobacter"},{"key":"5579_CR61","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1080\/19490976.2020.1754118","volume":"11","author":"CS Bang","year":"2020","unstructured":"Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS et al (2020) Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes 11:1314\u20131323","journal-title":"Gut Microbes"},{"key":"5579_CR62","volume-title":"Vonoprazan-Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection","author":"W Gao","year":"2026","unstructured":"Gao W, Li J, Yang G, Du S, Ling T, Zhang X et al (2026) Vonoprazan-Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection. Randomized Controlled Trial, Gastroenterology"},{"key":"5579_CR63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1254\/fpj.152.104","volume":"152","author":"J Matsukawa","year":"2018","unstructured":"Matsukawa J, Inatomi N, Nishida H, Tsukimi Y (2018) [Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate]. Nihon Yakurigaku Zasshi 152:104\u2013110","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"5579_CR64","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M et al (2016) Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 43:1048\u20131059","journal-title":"Aliment Pharmacol Ther"},{"key":"5579_CR65","doi-asserted-by":"publisher","first-page":"e12947","DOI":"10.1111\/hel.12947","volume":"28","author":"W Gao","year":"2023","unstructured":"Gao W, Xu Y, Liu J, Wang X, Dong X, Teng G et al (2023) A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies. Helicobacter 28:e12947","journal-title":"Helicobacter"},{"key":"5579_CR66","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/gutjnl-2024-332640","volume":"73","author":"W Gao","year":"2024","unstructured":"Gao W, Liu J, Wang X, Li J, Zhang X, Ye H et al (2024) Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy. Gut 73:1414\u20131420","journal-title":"Gut"},{"key":"5579_CR67","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1186\/s12879-024-09885-x","volume":"24","author":"S Huang","year":"2024","unstructured":"Huang S, Li B, Pang XY, Gao WW (2024) Efficacy and safety of Vonoprazan-based treatment of Helicobacter pylori infection: a systematic review and network meta-analysis. BMC Infect Dis 24:953","journal-title":"BMC Infect Dis"},{"key":"5579_CR68","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fphar.2019.00316","volume":"10","author":"ATB Abadi","year":"2019","unstructured":"Abadi ATB, Ierardi E (2019) Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon? Front Pharmacol 10:316","journal-title":"Front Pharmacol"},{"key":"5579_CR69","doi-asserted-by":"crossref","unstructured":"Miftahussurur M, Pratama Putra B, Yamaoka Y (2020) The potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals (Basel) 13:276","DOI":"10.3390\/ph13100276"},{"key":"5579_CR70","doi-asserted-by":"publisher","first-page":"175628482513148","DOI":"10.1177\/17562848251314801","volume":"18","author":"T Jin","year":"2025","unstructured":"Jin T, Wu W, Zhang L, Xuan H, Zhang H, Zhong L (2025) The efficacy and safety of Vonoprazan and Tegoprazan in Helicobacter pylori eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials. Ther Adv Gastroenterol 18:17562848251314801","journal-title":"Ther Adv Gastroenterol"},{"key":"5579_CR71","doi-asserted-by":"publisher","first-page":"e70106","DOI":"10.1111\/hel.70106","volume":"31","author":"JY Park","year":"2026","unstructured":"Park JY, Hong SJ, Choi IJ, Baik GH, Kim SM, Park JJ et al (2026) Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial. Helicobacter 31:e70106","journal-title":"Helicobacter"},{"key":"5579_CR72","doi-asserted-by":"publisher","first-page":"696","DOI":"10.5009\/gnl250067","volume":"19","author":"JY Park","year":"2025","unstructured":"Park JY, Choi IJ, Kim GH, Hong SJ, Shin SK, Jeon SW et al (2025) Comparative Efficacy of Potassium-Competitive Acid Blocker-Based Triple Therapy with Tegoprazan versus Vonoprazan for Helicobacter pylori Eradication: A Randomized, Double-Blind, Active-Controlled Pilot Study. Gut Liver 19:696\u2013705","journal-title":"Gut Liver"},{"key":"5579_CR73","doi-asserted-by":"crossref","unstructured":"Cho JH (2025) Tegoprazan-amoxicillin dual therapy for clarithromycin-resistant Helicobacter pylori: a feasibility pilot study. Microorganisms 13:2408","DOI":"10.3390\/microorganisms13102408"},{"key":"5579_CR74","doi-asserted-by":"publisher","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","volume":"118","author":"HS Qian","year":"2023","unstructured":"Qian HS, Li WJ, Dang YN, Li LR, Xu XB, Yuan L et al (2023) Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. Am J Gastroenterol 118:627\u2013634","journal-title":"Am J Gastroenterol"},{"key":"5579_CR75","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1111\/hel.70062","volume":"30","author":"L Tao","year":"2025","unstructured":"Tao L, Qian H, Zhang L, Luo P, Ma S, Yan J et al (2025) Optimizing Duration and Dosing Frequency of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori: A Multicenter Randomized Trial. Helicobacter 30:e70062","journal-title":"Helicobacter"},{"key":"5579_CR76","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10238-025-02037-8","volume":"26","author":"YY Han","year":"2026","unstructured":"Han YY, Li JY, Zhou YN, Tuo L, Wang G, Liu JM et al (2026) Comparative effectiveness and safety of vonoprazan\/amoxicillin-based dual therapy versus quadruple therapy as second-line treatment for Helicobacter pylori Infection: a retrospective cohort study. Clin Exp Med 26:119","journal-title":"Clin Exp Med"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05579-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:04:55Z","timestamp":1789999495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05579-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5579"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05579-1","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}